Save

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

PHASE1PHASE2RECRUITING

This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.

Simpliy with AI

Study details:

This is a first in-human study of AZD8421 administered to participants with advanced or metastatic solid tumors. The study will evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics, and pharmacodynamics of AZD8421 alone and in combination with selected targeted anti-cancer drugs. AZD8421 monotherapy (M1) will evaluate the safety, tolerability and pharmacokinetics of AZD8421 as monotherapy to identify a recommended Phase II dose (RP2D) in participants with ER+ HER2- advanced breast cancer previously treated with a CDK4/6i (Parts A and B) and participants with metastatic high-grade serous ovarian cancer previously treated with a platinum-based chemotherapy in the metastatic setting (Part B).

AZD8421 combination therapy (M2) will evaluate the safety, tolerability, and pharmacokinetics of AZD8421 in combination with a CDK4/6 inhibitor (one or more of abemaciclib, ribociclib and palbociclib) and camizestrant (next generation oral SERD; referred to throughout as 'camizestrant') in participants with ER+ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Female participants only, aged 18 or above

Participants with advanced solid tumors must have received prior adequate therapy in accordance with local practice for their tumor type and stage of disease, or, in the opinion of the Investigator, a clinical study is the best option for their next treatment based on response to and/or tolerability of prior therapy.

Metastatic or locoregionally recurrent disease and radiological or objective evidence of progression on or after the last systemic therapy prior to starting IMP.

ECOG/WHO performance status 0 to 1, and a minimum life expectancy of 12 weeks.

At least one lesion that is measurable and/or non-measurable, as per RECIST v1.1 and that can be accurately assessed at baseline and is suitable for repeated assessment.

Exclusion criteria

Intervention with any of the following:

Any cytotoxic chemotherapy, investigational agents, or other anti-cancer drugs for the treatment of advanced cancer from a previous treatment regimen or clinical study within 14 days or 5 half-lives (whichever is shorter) of the first dose of IMP (21 days for myelosuppressive therapies) other than GnRHa (eg, goserelin) and bone-stabilizing agents (eg, zoledronic acid, denosumab).

Any prescription or non-prescription drugs or other products, including herbal products, known to be moderate or strong inhibitors/inducers of CYP3A4/5 which cannot be discontinued prior to first dose of IMP and withheld throughout the study until 2 weeks after the last dose of study drug.

Drugs that have a known risk of Torsades de Pointes.

Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of IMP.

Major surgical procedure or significant traumatic injury, within 4 weeks of the first dose of IMP, or an anticipated need for major surgery and/or any surgery requiring general anesthesia during the study.

Any unresolved toxicities of Grade ≥ 2 from prior anti-cancer therapy (with the exception of alopecia). Participants with stable ≤ Grade 2 neuropathy are eligible.

Presence of life-threatening metastatic visceral disease, as judged by the Investigator, uncontrolled CNS metastatic disease. Participants with spinal cord compression and/or brain metastases may be enrolled if definitively treated (eg, surgery or radiotherapy) and stable off steroids for at least 4 weeks prior to start of IMP.

Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, or eg, infection requiring IV antibiotic therapy, or active infection including hepatitis B, hepatitis C, and HIV (active viral infection is defined as requiring antiviral therapy; screening for chronic conditions is not required).

Any of the following cardiac criteria:

Mean resting QTcF > 470 msec obtained from a triplicate ECG

Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG (eg, complete left bundle branch block, second- and third-degree heart block), or clinically significant sinus pause. Participants with controlled atrial fibrillation can be enrolled.

Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as symptomatic heart failure, hypokalemia, congenital long QT syndrome, immediate family history of long QT syndrome or unexplained sudden death at < 40 years of age. Hypertrophic cardiomyopathy and clinically significant stenotic valve disease.

LVEF < 50%, and/or experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, unstable angina pectoris, congestive heart failure NYHA Grade ≥ 2, cerebrovascular accident, or transient ischemic attack.

Uncontrolled hypertension.

Inadequate bone marrow reserve or organ function as demonstrated by relevant laboratory values:

Refractory nausea and vomiting, uncontrolled chronic gastrointestinal diseases, or previous significant bowel resection that would preclude adequate absorption of IMP(s).

History of hypersensitivity to active or inactive excipients of AZD8421 or drugs with a similar chemical structure or class to AZD8421.

Previous treatment with AZD8421 or with any CDK2-selective inhibitor, or protein kinase membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase 1 (PKMYT1) inhibitor, or WEE1 inhibitor.

Currently pregnant (confirmed with positive pregnancy test), breast feeding, or planning to become pregnant. Participants of childbearing potential must agree to use one highly effective contraceptive measure.

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : No

Gender eligible for study: Female

Things to know

Study dates

Study start: 2023-12-05

Primary completion: 2025-06-18

Study completion finish: 2025-06-18

Study type

TREATMENT

Phase

PHASE1

PHASE2

Trial ID

NCT06188520

Intervention or treatment

DRUG: AZD8421

DRUG: Camizestrant

DRUG: Ribociclib

DRUG: Palbociclib

DRUG: Abemaciclib

Conditions

• ER+ HER2- Advanced Breast Cancer
• High-grade Serous Ovarian Cancer (HGSOC)

Image related to ER+ HER2- Advanced Breast Cancer

Condition: ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
DRUG: AZD8421 and other drugs
East Melbourne, Not Specified, Australia
Sponsor: AstraZeneca

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Research Site

Research sites nearby

Select from list below to view details:

Research Site
East Melbourne, Not Specified, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Module 1 AZD8421 monotherapy	DRUG: AZD8421 CDK2 inhibitor
EXPERIMENTAL: Module 2A_abema AZD8421 with camizestrant and abemaciclib	DRUG: AZD8421 CDK2 inhibitor
EXPERIMENTAL: Module 2A_ribo AZD8421 with camizestrant and ribociclib	DRUG: AZD8421 CDK2 inhibitor
EXPERIMENTAL: Module 2A_palbo AZD8421 with camizestrant and palbociclib	DRUG: AZD8421 CDK2 inhibitor

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Incidence of dose limiting toxicities (DLTs) as defined in the protocol.	Percentage of participants with incidence of DLTs.	From start of treatment until the end of DLT period, assessed up to 28 days.
Incidence of AEs/SAEs	Percentage of participants with incidence of AEs/SAEs.	From start of treatment until the end of safety follow-up, approximately 18 months.
Clinically significant changes from baseline in clinical laboratory parameters, vital signs and ECGs.	Percentage of participants with clinically significant changes from baseline in clinical laboratory parameters, vital signs and ECGs.	From start of treatment until the end of safety follow-up, approximately 18 months.
Discontinuation of AZD8421 due to toxicity	Percentage of participants that have discontinued AZD8421 due to toxicity.	From start of treatment until the end of safety follow-up, approximately 18 months.

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Overall Response Rate (ORR)	The percentage of participants with a confirmed Complete Response (CR) or Partial Response (PR), according to RECIST v1.1, that occur prior to disease progression and/or initiation of subsequent anti-cancer therapy.	8 weeks from start of treatment until end of treatment or objective disease progression, approximately 18 months.
Duration of Response (DoR)	The time from the date of first documented objective response (which is subsequently confirmed) until date of first documented disease progression or death (by any cause in the absence of disease progression).	8 weeks from start of treatment until end of treatment or objective disease progression, approximately 18 months.
Disease control rate (DCR)	The percentage of participants who have a best objective response of confirmed CR or PR or who have SD for at least 23 weeks after start of treatment.	24 weeks after the start of treatment.
Percentage change in tumor size	The largest decrease (or smallest increase) in tumor size from baseline for a participant, using RECIST v1.1 assessments	From start of treatment through to EOT, progressive disease, death (in the absence of progression), start of subsequent anti-cancer therapy, whichever occurs first, approximately 18 months.
Progression Free Survival (PFS)	Progression-free survival is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy prior to progression.	From start of treatment through to progressive disease, death (in the absence of progression), EOT (last evaluable disease assessment), whichever occurs first, approximately 18 months.
PK of AZD8421 (Cmax)	To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After single dose; Cmax; to measure maximum plasma concentration after oral administration.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.
PK of AZD8421 (Tmax)	To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After single dose; Tmax; to measure time to reach maximum plasma concentration.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.
PK of AZD8421 (AUCinf)	To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After single dose; AUCinf; to measure the area under the plasma concentration-time curve from time 0 to infinity.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.
PK of AZD8421 (AUClast)	To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After single dose; AUClast; to measure area under the plasma concentration-time curve from time zero to last PK sample.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.
PK of AZD8421 (T1/2λZ)	To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After single dose; T1/2λZ; to measure the terminal elimination half-life.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.
PK of AZD8421 (CL/F)	To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After single dose; CL/F; to measure apparent clearance after oral administration.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.
PK of AZD8421 (Cssmax)	To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After multiple doses; Cssmax; to measure maximum concentration after oral administration at steady state.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.
PK of AZD8421 (Tssmax)	To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After multiple doses; Tssmax; to measure time it takes to achieve maximum plasma concentration at steady state.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.
PK of AZD8421 (AUC0-tau)	To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After multiple doses; AUC0-tau; to measure area under plasma-concentration time cure within dosing interval.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.
PK of AZD8421 (AUCsslast)	To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After multiple doses; AUCsslast; to measure the area under plasma-concentration time curve from time zero to last PK sample at steady state.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.
PK of AZD8421 (T1/2λssz)	To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After multiple doses; T1/2λssz; to measure terminal elimination half-life at steady state.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.
PK of AZD8421 (CLss/F)	To characterize the PK profiles and parameters of AZD8421 and its metabolites after monotherapy and also in combination with other anti-cancer drugs after single and multiple doses when administered to participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. Descriptive statistics of following PK parameters: After multiple doses; CLss/F; to measure apparent oral clearance at steady state.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421.
PK of AZD8421, camizestrant, and CDK4/6i (Cmax) (M2 only)	Evaluate pharmacokinetics profiles of AZD8421, camizestrant, and CDK4/6i when administered in combination. For AZD8421 and where possible CDK4/6i and their metabolites, and camizestrant; descriptive statistics of the following PK parameters: After single dose: Cmax; to measure maximum plasma concentration after oral administration.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421, camizestrant and CDK4/6i.
PK of AZD8421, camizestrant, and CDK4/6i (Tmax) (M2 only)	Evaluate pharmacokinetics profiles of AZD8421, camizestrant, and CDK4/6i when administered in combination. For AZD8421 and where possible CDK4/6i and their metabolites, and camizestrant; descriptive statistics of the following PK parameters: After single dose: Tmax; to measure the time it takes to achieve maximum plasma concentration after oral administration.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421, camizestrant and CDK4/6i.
PK of AZD8421, camizestrant, and CDK4/6i (AUCinf) (M2 only)	Evaluate pharmacokinetics profiles of AZD8421, camizestrant, and CDK4/6i when administered in combination. For AZD8421 and where possible CDK4/6i and their metabolites, and camizestrant; descriptive statistics of the following PK parameters: After single dose: AUCinf; to measure area under plasma concentration-time curve from time zero to infinity.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421, camizestrant and CDK4/6i.
PK of AZD8421, camizestrant, and CDK4/6i (T1/2λ) (M2 only)	Evaluate pharmacokinetics profiles of AZD8421, camizestrant, and CDK4/6i when administered in combination. For AZD8421 and where possible CDK4/6i and their metabolites, and camizestrant; descriptive statistics of the following PK parameters: After single dose: T1/2λZ; to measure terminal elimination half-life.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421, camizestrant and CDK4/6i.
PK of AZD8421, camizestrant, and CDK4/6i (CL/F) (M2 only)	Evaluate pharmacokinetics profiles of AZD8421, camizestrant, and CDK4/6i when administered in combination. For AZD8421 and where possible CDK4/6i and their metabolites, and camizestrant; descriptive statistics of the following PK parameters: After single dose: CL/F; to measure apparent clearance after oral administration.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421, camizestrant and CDK4/6i.
PK of AZD8421, camizestrant, and CDK4/6i (Cssmax) (M2 only)	Evaluate pharmacokinetics profiles of AZD8421, camizestrant, and CDK4/6i when administered in combination. For AZD8421 and where possible CDK4/6i and their metabolites, and camizestrant; descriptive statistics of the following PK parameters: After multiple doses: Cssmax; to measure the maximum plasma concentration after oral administration at steady state.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421, camizestrant and CDK4/6i.
PK of AZD8421, camizestrant, and CDK4/6i (Tssmax) (M2 only)	Evaluate pharmacokinetics profiles of AZD8421, camizestrant, and CDK4/6i when administered in combination. For AZD8421 and where possible CDK4/6i and their metabolites, and camizestrant; descriptive statistics of the following PK parameters: After multiple doses: Tssmax; to measure time it takes to achieve maximum plasma concentration after oral administration at steady state.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421, camizestrant and CDK4/6i.
PK of AZD8421, camizestrant, and CDK4/6i (AUC0-tau) (M2 only)	Evaluate pharmacokinetics profiles of AZD8421, camizestrant, and CDK4/6i when administered in combination. For AZD8421 and where possible CDK4/6i and their metabolites, and camizestrant; descriptive statistics of the following PK parameters: After multiple doses: AUC0-tau; to measure area under plasma-concentration-time curve within dosing interval.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421, camizestrant and CDK4/6i.
PK of AZD8421, camizestrant, and CDK4/6i (T1/2λssz) (M2 only)	Evaluate pharmacokinetics profiles of AZD8421, camizestrant, and CDK4/6i when administered in combination. For AZD8421 and where possible CDK4/6i and their metabolites, and camizestrant; descriptive statistics of the following PK parameters: After multiple doses: T1/2λssz; to measure terminal elimination half-life at steady state.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421, camizestrant and CDK4/6i.
PK of AZD8421, camizestrant, and CDK4/6i (CLss/F) (M2 only)	Evaluate pharmacokinetics profiles of AZD8421, camizestrant, and CDK4/6i when administered in combination. For AZD8421 and where possible CDK4/6i and their metabolites, and camizestrant; descriptive statistics of the following PK parameters: After multiple doses: CLss/F; to measure apparent clearance after oral administration at steady state.	From start of treatment, at predefined intervals up to Cycle 6, approximately 6 months (each cycle is 28 days) of the administration of AZD8421, camizestrant and CDK4/6i.
Overall survival (M1 and M2)	To assess the preliminary anti-tumor activity and efficacy of AZD8421 monotherapy/ or in combination with other anticancer drugs	From start of treatment through to death or study completion (last recorded date on which the subject was known to be alive), whichever occurs first, approximately 18 months.
PD of AZD8421 (M1B only)	To assess pharmacodynamic activity of AZD8421 monotherapy by assessment of candidate biomarkers in baseline and on-treatment tumor samples in participants with ER+ HER2- metastatic breast cancer and other advanced solid tumors. * Tumor protein analysis of candidate biomarkers. * Tumor assessment including, but not limited to: * Genomic profiling * Transcriptomic analysis * Proteomics * Epigenetic analyses * Immune profiling	From start of treatment, at predefined intervals throughout the administration of AZD8421 until end of treatment, approximately 18 months.

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors